Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease

STI571 is a selective tyrosine kinase inhibitor with proven therapeutic potential in malignancies expressing c-kit. A strong c-kit and stem cell factor expression was detected in the Hodgkin and Reed Sternberg cell line L1236, but not in 20 primary cases of classical Hodgkin's disease. Prolifer...

Descripción completa

Detalles Bibliográficos
Autores principales: Re, D, Wickenhauser, C, Ahmadi, T, Buchdunger, E, Kochanek, M, Diehl, V, Wolf, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375346/
https://www.ncbi.nlm.nih.gov/pubmed/11953894
http://dx.doi.org/10.1038/sj.bjc.6600243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375346/
https://www.ncbi.nlm.nih.gov/pubmed/11953894
http://dx.doi.org/10.1038/sj.bjc.6600243

Ejemplares similares